Voloridge Investment Management LLC Acquires 561,767 Shares of Genmab A/S (NASDAQ:GMAB)

Voloridge Investment Management LLC increased its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 102.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,110,191 shares of the company's stock after purchasing an additional 561,767 shares during the period. Voloridge Investment Management LLC owned about 0.17% of Genmab A/S worth $23,170,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of GMAB. Raymond James Financial Inc. bought a new stake in Genmab A/S in the fourth quarter valued at $2,463,000. AIMZ Investment Advisors LLC bought a new stake in Genmab A/S in the fourth quarter valued at $3,525,000. Mirae Asset Global Investments Co. Ltd. grew its position in Genmab A/S by 229.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company's stock valued at $1,033,000 after acquiring an additional 34,652 shares during the period. Blue Trust Inc. grew its position in Genmab A/S by 33.4% in the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock valued at $120,000 after acquiring an additional 1,442 shares during the period. Finally, Sei Investments Co. grew its position in Genmab A/S by 55.2% in the fourth quarter. Sei Investments Co. now owns 57,702 shares of the company's stock valued at $1,205,000 after acquiring an additional 20,525 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on GMAB shares. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. Sanford C. Bernstein cut Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Truist Financial decreased their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. Finally, Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Trading Down 1.4%

Shares of GMAB traded down $0.29 on Wednesday, reaching $20.99. 701,995 shares of the company's stock were exchanged, compared to its average volume of 1,131,263. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $28.96. The stock has a market capitalization of $13.46 billion, a P/E ratio of 12.05, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04. The business has a 50 day moving average price of $19.81 and a two-hundred day moving average price of $20.66.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. The business had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Equities research analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.